Mantle cell lymphoma in relapse: the role of emerging new drugs.
about
Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivoThe mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives.Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancerNovel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
P2860
Mantle cell lymphoma in relapse: the role of emerging new drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mantle cell lymphoma in relapse: the role of emerging new drugs.
@en
Mantle cell lymphoma in relapse: the role of emerging new drugs.
@nl
type
label
Mantle cell lymphoma in relapse: the role of emerging new drugs.
@en
Mantle cell lymphoma in relapse: the role of emerging new drugs.
@nl
prefLabel
Mantle cell lymphoma in relapse: the role of emerging new drugs.
@en
Mantle cell lymphoma in relapse: the role of emerging new drugs.
@nl
P1476
Mantle cell lymphoma in relapse: the role of emerging new drugs
@en
P2093
Owen A O'Connor
P304
P356
10.1097/CCO.0B013E32833D58F2
P577
2010-09-01T00:00:00Z